2018
DOI: 10.1007/s00592-018-1151-x
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
60
3
5

Year Published

2018
2018
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 97 publications
(73 citation statements)
references
References 25 publications
5
60
3
5
Order By: Relevance
“…However, 40% of eyes with DME are non-responders or suboptimal responders to anti-VEGF treatment (Bressler et al 2016;Gonzalez et al 2016). Dexamethasone (DEX) intravitreal implant 0.7 mg (Ozurdex Ò , Allergan, Inc., Irvine, CA, USA) has been shown to be effective in the treatment of DME with improvement in VA and decrease in retinal thickness (Boyer et al 2014;Guigou et al 2015;Iglicki et al 2018), even in eyes with DME refractory to anti-VEGF (Dutra Medeiros et al 2014;Alshahrani et al 2016;Pacella et al 2016;Busch et al 2018;Iglicki et al 2018).…”
Section: Introductionmentioning
confidence: 99%
“…However, 40% of eyes with DME are non-responders or suboptimal responders to anti-VEGF treatment (Bressler et al 2016;Gonzalez et al 2016). Dexamethasone (DEX) intravitreal implant 0.7 mg (Ozurdex Ò , Allergan, Inc., Irvine, CA, USA) has been shown to be effective in the treatment of DME with improvement in VA and decrease in retinal thickness (Boyer et al 2014;Guigou et al 2015;Iglicki et al 2018), even in eyes with DME refractory to anti-VEGF (Dutra Medeiros et al 2014;Alshahrani et al 2016;Pacella et al 2016;Busch et al 2018;Iglicki et al 2018).…”
Section: Introductionmentioning
confidence: 99%
“…10 The retrospective trial by Busch et al transitioned therapy after three monthly anti-VEGF injections and found a statistically significant improvement in vision if eyes were switched to dexamethasone at this stage compared to continued anti-VEGF therapy. 7 In a study by Todorich et al evaluating simultaneous dexamethasone implant therapy and anti-VEGF therapy in neovascular age-related macular degeneration (nAMD), patients who had improvement in BCVA with combination treatment had had a lower mean number of prior anti-VEGF injections (21.0 vs. 28.9). 11 Although the study was evaluating nAMD, these results support the possibility that earlier addition of corticosteroids in refractory eyes may lead to better visual outcomes.…”
Section: Additional Protocol Investigationsmentioning
confidence: 99%
“…In this study of 110 eyes, at 12 months, eyes that were switched to dexa- Practical Retina methasone improved by a mean 6.1 letters, whereas the arm continuing on anti-VEGF therapy lost 0.4 letters (P = .004). 7 Thus, the definition of persistent and refractory DME is of great significance in evaluating these results.…”
mentioning
confidence: 99%
“…Celem kolejnego real-life study, w którym wzięło udział 14 ośrodków z całego świata, było porównanie wyników leczenia doszklistkowymi iniekcjami czynnika anty-VEGF i DEX 0,7 mg u chorych z DME opornym na leczenie doszklistkowymi iniekcjami anty-VEGF w codziennej praktyce klinicznej [13]. W badaniu wzięło udział 105 chorych (110 oczu), a czas obserwacji wynosił 12 miesięcy.…”
Section: Rola Doszklistkowych Iniekcji Steroidów: Ozurdex -Dane Z Codunclassified
“…W metaanalizie obejmującej 3859 chorych z 15 badań oceniano skuteczność DEX 0,7 mg w leczeniu DME opornego na terapię anty-VEGF [13]. Analiza uzyskanych wyników wykazała, iż terapia z zastosowaniem DEX 0,7 mg poprawia w sposób istotny statystycznie BCVA, nawet w przypadku chorych, u których nie uzyskano odpowiedzi na leczenie doszklistkowymi iniekcjami czynnika anty-VEGF.…”
Section: Rola Doszklistkowych Iniekcji Steroidów: Ozurdex -Dane Z Codunclassified